US bank positive about Zealand's leaked fatty liver data
Zealand Pharma and partner Boehringer appear to be on the verge of publishing encouraging data from a study with the drug candidate Survodutide for the treatment of fatty liver disease, or MASH, according to US bank Jefferies.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.